Changing treatment: latest news

Changing treatment resources

Changing treatment features

Changing treatment in your own words

Changing treatment news from aidsmap

More news

Changing treatment news selected from other sources

  • Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

    I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

    20 September 2016 | BETA blog
  • Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

    Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial (TALENT Study) of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen (control) at 48-week in treatment experienced HIV-1 infected adults. In addition, patients administered with albuvirtide showed statistically better renal safety than those taking the control regimen containing tenofovir disoproxil fumarate.

    07 June 2016 | Frontier Biotech press release
  • HIV and drug resistance

    A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

    09 February 2016 | UNAIDS
  • Undetectable & Low-level HIV Viral Replication

    Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.

    06 January 2016 | BETA blog
  • Study: Protease Inhibitor Monotherapy Does Not Limit Future Treatment Options

    A recent study published in The Lancet HIV provides evidence that HIV maintenance therapy with a provider-selected boosted protease inhibitor (PI) regimen does not increase the risk of drug resistance and thus preserves future treatment options. But questions remain as to whether PI-monotherapy could be a clinically useful and relevant long-term HIV maintenance strategy.

    10 December 2015 | BETA blog
  • Study shows effectiveness of switching antiretroviral therapy for HIV-infected children

    A Columbia University study evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than three years, without risk of viral failure. The researchers reported that the treatment program resulted in excellent sustained virological control.

    06 November 2015 | Eurekalert Inf Dis
  • British HIV Association (BHIVA) 2015 Treatment Guidelines published

    The new BHIVA treatment guidelines recommend: "All individuals with HIV... are reviewed promptly by an HIV specialist and offered immediate ART." See http://www.aidsmap.com/page/2979458/ for a summary of the main recommendations.

    26 September 2015 | BHIVA
  • New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression

    ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regimen, Triumeq® (abacavir/dolutegravir/lamivudine) in virologically suppressed adults with HIV-1.

    23 September 2015 | Viiv Healthcare press release
  • Pretreatment HIV drug resistance leads patients to switch to second-line ART

    Recent data suggested that retreatment HIV drug resistance in sub-Saharan Africa was associated with a nearly fourfold increase in switching to second-line ART, but did not influence mortality or AIDS-related events.

    11 August 2015 | Healio
  • Dolutegravir and Truimeq approved in England: London guidelines updated

    On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

    14 January 2015 | HIV i-Base
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close